Objective The objective of this study was to determine the accuracy of body mass index (BMI) (pre-pregnancy or at booking) in predicting pre-eclampsia and to explore its potential for clinical application.
Introduction
Pre-eclampsia is a major cause of maternal and perinatal morbidity and mortality. [1] [2] [3] It has a long preclinical phase before signs and symptoms become manifest in the second half of pregnancy. Prediction of pre-eclampsia is important because increased monitoring and administration of early preventative treatment with, for example, aspirin can be more selectively targeted at high-risk women. 4 The exact aetiology of pre-eclampsia is still unknown. Several risk factors have been identified including obesity. 5 The World Health Organization (WHO) estimates that currently more than 1 billion adults are overweight, of whom at least 300 million are clinically obese. 6 From 1999 to 2003, in the total delivery population, the proportion of women who were overweight or obese pre-pregnancy increased from 37.1 to 40.5%. 7 This worldwide increase in overweight is likely to cause a rise in pre-eclampsia and other complications, such as gestational diabetes. 8 The body mass index (BMI) is an international standard for obesity measurement adjusting bodyweight for height (weight [kg]/height squared [m 2 ]) and an indicator of nutritional status.
We conducted a systematic review to determine the accuracy of BMI (pre-pregnancy or at booking) to predict preeclampsia and to explore its potential for clinical application. We meta-analysed the data using a bivariate regression analysis, accounting for (negative) correlation between sensitivity and specificity, and derived likelihood ratios (LRs) thereof. [9] [10] [11] [12] 
Methods

Study identification and selection
We performed an electronic search targeting all procedures used for the prediction of pre-eclampsia. We searched Medline, Embase, Cochrane Library, and MEDION (www. mediondatabase.nl/) from inception to April 2006. The search strategy 13 consisted of MeSH or keyword terms related to preeclampsia combined with methodological filters for identification of studies on diagnostic tests and aetiology. [14] [15] [16] We checked reference lists of review articles and eligible primary studies to identify cited articles not captured by electronic searches and contacted experts. Reference Manager 10.0 databases were established incorporating results of all searches.
We selected studies in a three-stage process. First, one reviewer scrutinised titles and/or abstracts of all citations. Second, to ensure independent duplicate selection for this review, we performed a search based on keywords '*weight* OR body mass* OR obesity OR adipos* OR fat OR quetelet*' within the Reference Manager database for citations to be scrutinised by a second reviewer. We obtained full manuscripts of all citations that were selected by at least one of the reviewers. Final in/exclusion decisions were made after independent and duplicate examination of the full manuscripts of selected citations. We included studies if they reported numerical data allowing construction of a 2 · 2 table cross-classifying BMI test results (pre-pregnancy or at booking) and occurrence of pre-eclampsia. We included studies examining pregnant women at any level of risk in any healthcare setting. Language restrictions were not applied. Any disagreements were resolved by consensus or by a third reviewer.
For each included paper, two reviewers independently extracted data on clinical and methodological study characteristics and on test accuracy. Study characteristics consisted of women's risk classifications, characteristics of the index test and of the reference standard, and details of the outcome, such as onset and severity of pre-eclampsia.
Assessment of study quality
Two reviewers independently assessed all included manuscripts for study quality according to an adapted version of QUADAS. 17 We considered consecutive or random entry of pregnant women to a cohort as ensuring an appropriate spectrum of patients. Patient selection criteria were considered appropriate when the study reported on parity, singleton/ multiple pregnancies, diabetes mellitus, and chronic hypertension. We deemed the reference standard for pre-eclampsia appropriate if it combined persistent systolic blood pressure ‡ 140 mmHg and/or diastolic blood pressure ‡ 90 mmHg with proteinuria ‡ 0.3 g/24 hours or ‡ 1+ dipstick (30 mg/dl in a single urine sample) new after 20 weeks of gestation. Similarly, we deemed the reference standard for superimposed pre-eclampsia appropriate when it combined the development of proteinuria ‡ 0.3 g/24 hours or ‡ 1+ dipstick after 20 weeks of gestation in chronically hypertensive women. 18, 19 A definition of pre-eclampsia according to recent (from the year 2000 onwards) international guidelines was also considered appropriate. [18] [19] [20] We also assessed if details of the index test (kg/m 2 , pre-pregnancy or before 20 weeks) and reference test (measurement device, position of patient, and Korotkoff phase), and a description of reasons for withdrawals were adequate.
Data synthesis
For each study, we constructed a 2 · 2 table cross-classifying BMI test results and the occurrence of pre-eclampsia. We used receiver operating characteristic (ROC) plots to visualise data. We used a bivariate meta-regression model to calculate pooled estimates of sensitivity and specificity for several BMI cutoff values and to fit a summary ROC (sROC) curve. This method has been extensively described elsewhere. [9] [10] [11] [12] Briefly, rather than using a single outcome measure per study, such as the diagnostic odds ratio, the bivariate model preserves the two-dimensional nature of diagnostic data in a single model. This model incorporates the correlation that may exist between sensitivity and specificity within studies due to possible differences in threshold between studies. The bivariate model uses a random effects approach for both sensitivity and specificity, allowing for heterogeneity beyond chance due to clinical or methodological differences between studies. In addition, the model acknowledges the difference in precision by which sensitivity and specificity have been measured in each study. This means that studies with a larger number of women with pre-eclampsia receive more weight in the calculation of the pooled estimate of sensitivity, while studies with more women without pre-eclampsia are more influential in the pooling of specificity. We calculated a correlation coefficient (r) to show the strength and shape of the correlation between sensitivity and specificity, and hence the amount of variance that can be explained due to threshold differences (r 2 ). Despite several cutoff values for BMI, for statistical reasons, each study was represented once in the sROC analysis. This was achieved by randomly sampling one 2 · 2 table from each study, ensuring that all areas of the sROC curve were represented. For clinical usefulness, we derived LRs from the estimated sensitivities and specificities.
We defined all subgroup analyses, except one (prepregnancy or at booking), a priori requiring that at least 80% of studies reported clearly on a particular item and each subgroup contained at least three studies. Data on threshold, pre-pregnancy or booking BMI, severity and onset (before or after 34 weeks) of pre-eclampsia, incidence (cutoff 4%), study design, consecutive entry, prospective data collection, and adequacy of reference standard were considered one by one in the subgroup analyses. First, we entered the subgroup characteristic as a covariate in the model. If homogeneity between studies with and without the characteristic was rejected (P < 0.10), the subgroup analysis was performed.
The bivariate models were fitted using the Proc NLMixed (SAS 9.1 for Windows [SAS Institute Inc, Cary, NC, USA]).
Potential for clinical application
At a (fixed) relative risk (RR) reduction of aspirin of 10% (RR = 0.90), 4 the absolute treatment effect becomes greater as the absolute risk rises. For a woman with a risk of preeclampsia of 40%, aspirin reduces it to 36%, whereas for a woman who has a 4% risk, this is reduced to 3.6%. Testing makes sense if treatment is conditional on obtaining a positive test result. Therefore, the impact of risk stratification using BMI depends on the shift that testing brings about in the pretest probability distribution. 21 We illustrated this impact with an example of decision-making in clinical practice about the use of aspirin in women at risk of pre-eclampsia, which has been shown to be an effective preventive treatment. 4 We calculated the risk, and hence the therapeutic benefits associated with BMI test results from sensitivity and specificity. The number needed to treat (NNTreat) is the number of women that one needs to treat (with aspirin) to prevent one case of pre-eclampsia and is calculated by 1/(probability after testing positive -probability after treatment). Figure 1 summarises the process of literature identification and selection. Thirty-six studies met the selection criteria. Four papers were found in reference lists, of which one was included. The two papers from Sebire et al. 46, 47 reported on the same cohort, and therefore, we considered it as one study. We excluded studies for a variety of reasons. The main reasons for exclusion were no distinction between pre-eclampsia and pregnancy-induced hypertension, insufficient data to construct a 2 · 2 table, and reporting weight or weight gain or a different weight-index test instead of a BMI. Table 1 summarises study characteristics. We included 23 cohort studies, 11 case-control studies, and one randomised trial. A total of 1 699 073 pregnant women were included, of whom 60 584 (3.6%) developed pre-eclampsia. The median incidence of pre-eclampsia in cohort studies was 3.9% (interquartile range 1.4-6.8). For calculation of the median incidence, we excluded case-control studies that did not report the incidence in their source population. The number of women analysed in cohort studies ranged from 281 27 to 561 770, 56 and in case-control studies from 54 37 to 6747. 28 Twenty-seven studies were performed in Western countries. Eleven studies were prospectively designed. Sixteen studies excluded all women with diabetes and/or chronic hypertension.
Results
Primary articles retrieved for detailed evaluation -fromelectronic searches n = 133 -from reference lists n = 4
Articles excluded n = 101 -no BMI calculated n = 22 -insufficient data toconstruct 2 x 2 table n = 20 -no pre-pregnancy BMI versus pre-eclampsia outcome n = 13 -reviews/ letters/ comments/ editorials n = 5 -pre-eclampsia not separate outcome/ pregnancy induced hypertension only n = 25 -matching on BMI n = 3 -gestational age unclear n = 1 -data duplication n = 7 -other n = 5
Primary articles included in meta-analysis n = 36
Potentially relevant citations identified from electronic searches to capture primary articles on all tests used in the prediction of pre-eclampsia n = 17-847
Potentially relevant citations on BMI in the prediction of pre-eclampsia n = 1-307
References excluded after screening titles and/ or abstracts n = 1-170 Figure 1 . Process from initial search to final inclusion for studies on BMI in the prediction of pre-eclampsia. Pre-pregnancy n.r.
(continued)
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Twenty-eight studies reported pre-pregnancy BMI, and seven studies reported BMI at booking. We excluded one study for the meta-analysis because this study excluded women with a BMI between 27 and 34. 25 Figure 2 summarises study quality. Patient recruitment, selection criteria, and reasons for withdrawal were poorly reported. Eleven studies used a definition of pre-eclampsia according to current international standards. Fifteen studies reported a definition of pre-eclampsia according to former guidelines. Details of how the reference test was executed were seldom reported. Only one study reported whether women received treatment to prevent pre-eclampsia. 48 Figure 3 shows the sROC curve for the included studies. The area under the curve (AUC) was 0.64, which was similar to the AUC representing all data points for all studies (AUC 0.63). The correlation coefficient was -0.965, indicating that 93% of heterogeneity could be explained due to differences in threshold for a positive test. Subgroup analysis on pre-pregnancy BMI versus BMI at booking yielded statistically significant differences (P < 0.0001), showing slightly better performance for pre-pregnancy BMI. However, their clinical relevance seems doubtful (sensitivity pre-pregnancy 48.1% (47.9-48.2) versus sensitivity at booking 44.9% (44.4-45.5) and specificity pre-pregnancy 61.4% (61.4-61.5) versus specificity at booking 58.5% (58.5-58.6). The discrepancy between statistical significance and clinical relevance is due to some of the studies having very large sizes. Below, we report the overall results. Incidence of pre-eclampsia, study design, data collection, and adequacy of reference standard did not further reduce heterogeneity. Analyses on clinical characteristics and consecutive entry were hindered by a lack of reporting. We used cutoff values that were most often used and reported by the Institute of Medicine (IOM) and WHO for categorisation. 6, 58 Pooled estimates (95% CI) for all studies with a BMI ‡ 25 (18 studies) were 47% (33-61) for sensitivity and 73% (64-83) for specificity. For a BMI ‡ 30 (19 studies), these estimates were 19% (19) (20) and 90% (88-93), and for a BMI ‡ 35 (4 studies), the estimates were 21% (12-31) and 92% (89-95). Pooling data on BMI ‡ 30 required an adjusted 
,9
weeks IN: normotensive women; EX: first visit after 9 weeks of gestation, CH, DM and cardiovascular disease CH, chronic hypertension; DM, diabetes mellitus; EX, excluded; IN, included; n.r., not reported; PET, pre-eclampsia. Table 2 shows that the probability of pre-eclampsia after positive BMI testing increases strongly in moderate (say incidence 7%) and high-risk (say 12%) populations to 18 and 29%, respectively, for women with a BMI ‡ 35. These latter posttest probabilities correspond with NNTs aspirin of 62 and 37, respectively. BMI results < 35 lead to posttest probabilities of 1.2, 5.9, and 10.7% in populations with a baseline risk of 1.4, 6.8, and 12.2%, respectively. These numbers, in turn, correspond to NNTs aspirin of 830, 170, and 94.
Discussion and conclusion
Based on a huge body of evidence, BMI (at any cutoff), prepregnancy or at booking, appears to be a fairly weak predictor for pre-eclampsia. Although BMI is virtually free of cost, noninvasive, and ubiquitously available, its usefulness as a standalone test for risk stratification must await formal cost-utility analysis. The findings of this review may serve to populate such a model.
Based on the estimates in this review, among low-risk pregnancies without testing, one needed to treat 714 women with aspirin to prevent one case of pre-eclampsia. By contrast, in high-risk women, who in addition have a BMI ‡ 35, one needed to treat only 37 women to prevent one case. This may seem impressive. However, it is not entirely clear how clinicians may decide on the exact risk level a woman has before modifying it further using BMI. Note also that a single test with modest values of sensitivity implies that many with a negative test result will develop pre-eclampsia and thus, in this example, will not benefit from what appears to be the 60 Duckitt and Harrington, 61 in their review, covering different tests at booking, included ten studies on BMI and reported different summary estimates, without explaining why they selected a RR of pre-eclampsia of 2.47 in their abstract. In addition, their methodology is flawed by the adoption of a cause-effect framework discarding studies with baseline incomparability, although this is unimportant in (noncausal) studies on prediction. 62 Finally, a pooled RR (of 2.47) does not allow clinicians to update their pre-test pre-eclampsia probabilities for women below the cutoff value, since such women remain on their prior probability. In contrast, we pooled sensitivities and specificities, which are less susceptible to variations in prevalence 60 and are more useful in determining whether the posttest probability increases or decreases for the various BMI categories. The mechanism by which obesity causes pre-eclampsia is not completely understood, although establishing a causal link is not particularly relevant for purposes of developing a predictive test. Obesity has a strong link with insulin resistance and predisposes for type II diabetes and gestational diabetes. Both obesity and diabetes are associated with a higher risk of cardiovascular diseases, and hence preeclampsia. 5, 63, 64 Hyperinsulinaemia may directly predispose to hypertension by increased renal sodium reabsorption and stimulation of the sympathetic nervous system. Another possible explanation is that insulin resistance and/or associated hyperglycaemia impair endothelial function. 5, 64 Studies that include a high proportion of women with diabetes or chronic hypertensive may thus find higher estimates for test accuracy of BMI. In contrast, smoking reduces the risk of pre-eclampsia and has no effect on the risk of gestational diabetes. 65, 66 Smokers usually have a lower BMI than nonsmokers, however, this effect is reduced when they quit smoking. 67 Our estimates of predictive accuracy may be biased due to the inability to adjust for these factors. However, this drawback holds for all meta-analyses focusing on evaluation of a single test, whereas in clinical practice more information is available.
Identification of primary studies on pre-eclampsia and BMI in database searches is difficult. In primary studies, BMI is often reported as a secondary 'exposure' in a table showing some general population characteristics. Electronic retrieval is possible only when BMI is mentioned in the title, abstract, or as a keyword. Factors that may influence the predictive accuracy of BMI are poor reporting of selection criteria, preventive treatment, and self-reported weight and height. Self-reported weight in particular may be underestimated in women 68 and may result in a lower BMI (more test negatives), thus lowering sensitivity and raising specificity. However, a subgroup analysis on pre-pregnancy BMI versus BMI at booking did not indicate this to be a strong phenomenon, although statistically significant. Due to lack of reporting on early and late onset, and on severity of pre-eclampsia, we were unable to estimate the predictive accuracy of BMI for severe early onset pre-eclampsia, which has considerable maternal and perinatal morbidity and mortality. 2, 3 Future research should focus on undertaking high-quality primary studies of test accuracy including all risk indicators that clinicians normally use. This will enable future reviewers to focus on meta-analysis of adjusted accuracy parameters or, even better, on meta-analysis using individual patient data. 69 The proper role of BMI among other tests in rational risk stratification strategies for pre-eclampsia must await the results from such analyses ideally incorporating the costs and benefits of preventive treatment.
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